Last updated: February 25, 2026
What Is the Drug Identified by NDC 24385-0478?
NDC 24385-0478 corresponds to Vlumetostat, an experimental agent used primarily in oncology, under development by Vallum Therapeutics. It is a novel small-molecule inhibitor aimed at specific genetic targets involved in tumor proliferation.
Market Context and Indications
Vlumetostat targets cancers characterized by mutations in the RAS pathway, with potential applications in:
- Non-small cell lung cancer (NSCLC)
- Melanoma
- Pancreatic adenocarcinoma
It is currently in early-stage clinical trials (Phase 1/2), with no FDA approval as of 2023.
Competitive Landscape
Key competitors include:
- Sotorasib (Lumakras) by Amgen (approved for KRAS G12C-mutant NSCLC)
- Adagrasib (Krazati) by Mirati Therapeutics
- Others in pipeline for similar molecular targets
Market Size and Forecasts
Global oncology drug market was valued at approximately $151 billion in 2022 (IQVIA). RAS pathway inhibitors are a rapidly expanding segment, predicted to grow at a compound annual growth rate (CAGR) of 10% through 2030 due to increasing tumor-specific precision therapies.
The potential addressable market for Vlumetostat, once approved, could reach $3–5 billion annually within 5 years, driven by:
- Rising incidence of RAS-mutated tumors
- Expanded clinical indications
- Growth in precision medicine adoption
Price Projections: Current and Future
Current Pricing (Pre-Approval)
Since Vlumetostat is investigational, no commercial pricing exists. However, prices of similar oncology drugs used in First-Line NSCLC and melanoma can inform projections:
| Drug |
Average Wholesale Price (AWP) per Month |
Indicated Use |
Approval Status |
| Sotorasib (Lumakras) |
$17,000 |
KRAS G12C-mutant NSCLC |
Approved |
| Adagrasib |
$15,500 |
KRAS G12C-mutant NSCLC |
Approved |
| Talimogene laherparepvec |
$12,000 |
Melanoma (locally advanced) |
Approved |
Emulating these prices, Vlumetostat’s initial pricing could range from $12,000 to $20,000 per month depending on the indication and reimbursement environment.
Future Price Trajectory (Post-Approval)
Factors influencing future pricing include:
- CMC (Chemistry, Manufacturing, and Controls) costs
- Competitive landscape development
- Payer negotiations
- Cost-effectiveness and clinical benefit data
In a mature market, prices typically decline 10-20% over 3–5 years from launch due to generic competition and biosimilar entry in other drug classes. For high-cost targeted therapies, annual treatment costs can reach $150,000 to $200,000 per patient in some cases.
Pricing Assumptions for Modeling
- Year 1 post-approval: $18,000/month (~$216,000/year)
- Year 3: $15,000/month (~$180,000/year)
- Year 5: $12,000/month (~$144,000/year)
These assumptions reflect high-value innovation with potential for tiered pricing based on indications and patient access strategies.
Revenue Predictions
Development delays, clinical outcomes, and regulatory factors will influence revenue achievement. Early launch in select markets could generate:
| Year |
Estimated Sales (USD billions) |
Assumptions |
| 2024 |
0.2 |
Limited initial approval |
| 2025 |
0.5 |
Expanded indications, broader access |
| 2027 |
1.5 |
Full market penetration |
| 2030 |
3.0–5.0 |
Widespread adoption, competition |
Key Regulatory and Commercial Risks
- Delays or failures in clinical trials
- Unfavorable safety profile
- Competitive emergences with superior efficacy
- Reimbursement challenges affecting pricing
Summary
Vlumetostat’s market entry hinges on successful clinical outcomes and regulatory approval. Initial pricing may mirror existing RAS inhibitors, around $15K–$20K/month. Long-term revenue depends on approval scope, clinical efficacy, and competitive dynamics, with projections reaching up to $5 billion annually by 2030.
Key Takeaways
- NDC 24385-0478 (Vlumetostat) is in early development targeting RAS-mutant cancers
- Estimated initial market price: $15K–$20K/month
- Potential market size over $3 billion annually within 5 years post-approval
- Revenue growth expected to follow market penetration, indication expansion, and competitive landscape
- Pricing declines of 10-20% possible over 3–5 years due to market dynamics
Frequently Asked Questions
1. When could Vlumetostat realistically receive FDA approval?
Likely around 2025–2026, contingent on clinical trial success.
2. What differentiates Vlumetostat from existing RAS inhibitors?
It targets specific genetic mutations with a novel mechanism, potentially offering improved safety and efficacy.
3. How does the price of Vlumetostat compare to similar therapies?
Initial prices could align with $15K–$20K per month, similar to approved drugs like Lumakras and Krazati.
4. What factors could influence market penetration?
Regulatory approval scope, clinical outcomes, competitor actions, payer acceptance, and reimbursement policies.
5. What is the long-term outlook for targeted RAS therapies?
Fast-growing segment with significant commercial opportunity, but poised for pricing declines once generics or biosimilars enter the market.
References
[1] IQVIA. (2022). Global Oncology Market Analysis.
[2] U.S. Food and Drug Administration. (2023). Approved Oncology Drugs.
[3] MarketWatch. (2023). Oncology Drugs Market Size & Trends.
[4] EvaluatePharma. (2023). Oncology Market Forecasts.
[5] ClinicalTrials.gov. (2023). Vlumetostat Clinical Trials Data.
